Better Therapeutics Receives FDA Authorization For AspyreRx To Treat Adults With Type 2 Diabetes; Demonstrated Clinically Meaningful And Statistically Significant Durable Reductions In A1c
Portfolio Pulse from Happy Mohamed
Better Therapeutics has received FDA authorization for AspyreRx, a prescription digital therapeutic treatment for adults with type 2 diabetes. The treatment demonstrated significant reductions in A1c in a randomized controlled trial. The company plans to commercially launch AspyreRx in Q4 2023. The FDA's authorization creates a new class of diabetes digital behavioral therapeutic devices.
July 10, 2023 | 8:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Better Therapeutics' FDA authorization for AspyreRx could potentially boost the company's stock in the short term. The commercial launch of AspyreRx in Q4 2023 could provide a new revenue stream for the company.
The FDA authorization is a significant regulatory milestone for Better Therapeutics, which could positively impact investor sentiment and drive the stock price up in the short term. The commercial launch of AspyreRx in Q4 2023 could provide a new revenue stream for the company, further boosting its financial performance and potentially its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100